Ophthalmic Complications in Inflammatory Bowel Disease
DOI:
https://doi.org/10.58931/cibdt.2024.2232Abstract
The prevalence of inflammatory bowel disease (IBD), estimated at 843 per 100,000 people (95% PI 828-859) (i.e., 0.843% of the population) in 2023 is increasing in Canada and is expected to reach 1.1% of the Canadian population by 2035. Consequently, extraintestinal manifestations and complications will also increase. Up to 50% of patients suffering from IBD will develop an extraintestinal manifestation (EIM) during the course of their disease, patients with Crohn’s disease (CD) being more often affected then those with ulcerative colitis (UC). Ocular manifestations are the third most common EIM after articular and dermatological involvements. Ocular complaints in patients with IBD can represent an EIM, a complication of systemic treatment or an unrelated affection. All patients presenting with a red eye, light sensitivity, loss of vision or any acute ocular symptom(s) should be promptly evaluated by an eye specialist. Early detection of ophthalmologic diseases and appropriate management require collaboration between specialists and are of utmost importance to avoid permanent visual loss.
The most common ocular manifestations reported in IBD patients are episcleritis (2-5%) and anterior uveitis (0.5-3.5%). Other less common manifestations include scleritis, intermediate and posterior uveitis, retinal vasculitis, retinal vascular occlusions, orbital inflammatory syndrome, and optic neuritis. Ocular manifestations can also be associated with malabsorption syndromes encountered in some patients with IBD. Secondary vitamin A deficiency can result in night blindness and keratoconjunctivitis sicca.
References
Kuenzig E, Kaplan G, Benchimol E. The Rising Burden Of Inflammatory Bowel Disease In Canada: Findings From The Crohn’s And Colitis Canada 2023 Impact Of Inflammatory Bowel Disease In Canada Report. Can IBD Today [Internet]. 2024 Jun. 5 [cited 2024 Aug. 5];2(1):5–11. Available from: https://canadianibdtoday.com/article/view/2-1-Kuenzig_et_al
Harbord M, Annese V, Vavricka SR, et al; European Crohn’s and Colitis Organisation. The first European evidencebased consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016 Mar;10(3):239-54. DOI: https://doi.org/10.1093/ecco-jcc/jjv213
Pytrus W, Akutko K, Pytrus T, et al. A review of ophthalmic complications in inflammatory bowel diseases. J Clin Med. 2022 Dec 15;11(24):7457. DOI: https://doi.org/10.3390/jcm11247457
Mady R, Grover W, Butrus S. Ocular complications of inflammatory bowel disease. Scientific World Journal. 2015;2015:438402. DOI: https://doi.org/10.1155/2015/438402
Pereira A, Adekunle RD, Zaman M, et al. Association between vitamin deficiencies and ophthalmological conditions. Clin Ophthalmol. 2023;17:2045-62. DOI: https://doi.org/10.2147/OPTH.S401262
da Rocha Lima B, Pichi F, Lowder CY. Night blindness and Crohn’s disease. Int Ophthalmol. 2014;34:1141–1144. DOI: https://doi.org/10.1007/s10792-014-9940-x
Abegunde AT, Muhammad BH, Ali T. Preventive health measures in inflammatory bowel disease. World J Gastroenterol. 2016;22:7625-44. DOI: https://doi.org/10.3748/wjg.v22.i34.7625
Mintz R, Feller E, Bahr RL, et al. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(2):135-9. DOI: https://doi.org/10.1097/00054725-200403000-00012
Troncoso LL, Biancardi AL, de Moraes HV Jr, et al. Ophthalmic manifestations in patients with inflammatory bowel disease: A review. World J Gastroenterol. 2017 Aug 28;23(32):5836-48. DOI: https://doi.org/10.3748/wjg.v23.i32.5836
Lin H, Zhang J, Liang C, et al. Differences in the prevalence of uveitis between Crohn's disease and ulcerative colitis: A systematic review and meta-analysis. Acta Ophthalmol. 2024 Jun;102(4):e485-e492. DOI: https://doi.org/10.1111/aos.15793
Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509-16. DOI: https://doi.org/10.1016/j.ajo.2005.03.057
Vera EL, Betancur Vasquez CB, Peinado Acevedo JS, et al. Ocular manifestations of inflammatory bowel disease. Cureus. 2023 Jun 12;15(6):e40299.
Biedermann L, Renz L, Fournier N, et al. Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. Therap Adv Gastroenterol. 2019 Aug 13;12:1756284819865142.
Ottaviano G, Salvatore S, Salvatoni A, et al. Ocular manifestations of paediatric inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2018 Jun 28;12(7):870-9. DOI: https://doi.org/10.1093/ecco-jcc/jjy029
Schwartzman S. Advancements in the management of uveitis. Best Pract Res Clin Rheumatol. 2016 Apr;30(2):304-15. DOI: https://doi.org/10.1016/j.berh.2016.07.005
Levy-Clarke G, Nussenblatt R. Does anti-TNF therapyzdecrease the incidence of anterior uveitis in patients with ankylosing spondylitis? Nat Clin Pract Rheumatol. 2006 Feb;2(2):72-3. DOI: https://doi.org/10.1038/ncprheum0097
Rudwaleit M, Rødevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009 May;68(5):696-701. DOI: https://doi.org/10.1136/ard.2008.092585
Dubinsky MC, Cross RK, Sandborn WJ, et al. Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients With inflammatory bowel disease. Inflamm Bowel Dis. 2018 Aug 16;24(9):1876-82. DOI: https://doi.org/10.1093/ibd/izy065
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Canadian IBD Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
